Bladder Cancer VL

Role of Blue Light Cystoscopy in Bladder Cancer Management - Trinity Bivalacqua

Details
Trinity Bivalacqua joins Ashish Kamat to discuss the role of blue light cystoscopy in bladder cancer treatment, specifically regarding non-muscle invasive disease. Dr. Bivalacqua emphasizes how risk stratification allows for personalization of care and highlights a case study of a patient with high-risk non-muscle invasive bladder cancer. Dr. Bivalacqua also explains how blue light cystoscopy can...

Bladder Preservation Protocols for Muscle-Invasive Urothelial Carcinoma - Arjun Balar

Details
Joining Alicia Morgans at ASCO GU is Arjun Balar, a bladder cancer expert at New York University, who speaks to the most recent clinical trials and the future direction of available regimens regarding bladder preservation protocols. For the past 30 years, muscle-invasive urothelial cancer patients have been given two options for treatment: radical cystectomy or cisplatinum. With the more recent av...

Weathering the Current BCG Shortage Crisis - Michael O’Donnell

Details
Michael O'Donnell shares his insight into managing the current BCG shortage crisis, highlighting ways to make the most out of the current supply and explains a few alternative intravesical agents that could be used in place of BCG for treating patients with bladder cancer. Dr. O'Donnell explains how risk can be assessed while prioritizing high-risk patients and shares advice as to how treatment pl...

Blue Light Cystoscopy with Cysview for Management of Non Muscle Invasive Bladder Cancer - Joshua Meeks

Details
Joshua Meeks joins Alicia Morgans to review his approach to cystoscopy using blue light and Cysview®, and how to best choose patients that will maximally benefit from that kind of technology. Dr. Meeks and Dr. Morgans also review the new approval of pembrolizumab in the BCG unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). Biographies: Josh J. Meeks, MD, Ph.D., Assistant Professor...

Implications of the Bacillus Calmette-Guérin (BCG) Shortage - Joshua Meeks

Details
Joshua Meeks joins Alicia Morgans to discuss the current BCG shortage and its implications for treatment options in the bladder cancer community. Dr. Meeks highlights clinical data on the matter presented by other clinicians at the conference, as well as his own personal expertise on how he manages the patient selection and the risk stratification process for BCG resources in his own clinic. Biogr...

Improving Research and Clinical Care, Bladder Cancer in Women - Jean Hoffman-Censits

Details
Medical Oncologist and co-leader of the Women's Bladder Cancer Program at John Hopkins, Jean Hoffman-Censits joins Alicia Morgans to speak about bladder cancer in women and the initiatives and importance of the Women's Bladder Cancer Program. In many cases, there are significant delays in diagnosing bladder cancer in women. Dr. Hoffman-Censits discusses the continuous narrative of the delay in dia...

Current and Emerging Therapies for Non-Muscle Invasive Bladder Cancer after BCG - Chris Wallis & Zach Klaassen

Details
For this Journal Club, Christopher Wallis, MD, and Zach Klasseen, MD discuss a recently published meta-analysis on treatment options for patients with non-muscle invasive bladder cancer unresponsive or refractory to BCG therapy. They provide context for this review and discuss the clinical relevance of managing the risk of recurrence in NMIBC. Biographies: Zachary Klaassen, MD, MSc, Urologic Oncol...

Phase III Nadofaragene Firadenovec for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Joshua J. Meeks

Details
In this discussion, Josh Meeks joins Alicia Morgans to review the new advances phase III Nadofaragene Firadenovec (Adstiladrin®) trial for BCG unresponsive non-muscle invasive bladder cancer patients. Dr. Meeks details the results of this recently presented trial data and why he believes this is the beginning of the next era in treating these patients. Biographies: Josh J. Meeks, MD, Ph.D., Assist...

Research and Clinical Practice Strategies Due to the BCG Shortage - Sam S. Chang

Details
Sam Chang joins Ashish Kamat to discuss strategies for clinical trials and patient selection required in the face of the world-wide shortage of BCG. Biographies: Sam S. Chang, MD, MBA , Patricia and Rodes Hart Endowed Chair of Urologic Surgery Professor Department of Urology at Vanderbilt University Medical Center, Department of Urology Ashish Kamat, MD, MBBS Professor of Urology and Wayne B. Dudd...

Bladder Cancer Research That Impacts Urology Clinical Practice - Josh Meeks

Details
Joshua Meeks joins Ashish Kamat in discussing the most recent relevant research papers in bladder cancer. Together they explore the publications on checkpoint inhibitors, the use of The Cancer Genome Atlas, Enhanced Recovery after Cystectomy and the impact of blue light flexible cystoscopy with CYSVIEW. Biographies: Josh J. Meeks, MD, Ph.D., Assistant Professor of Urology and Biochemistry and Mole...
email news signup